Ranbaxy Says Second Phase Trial Indicates Promise For Malaria Drug
This article was originally published in PharmAsia News
Executive Summary
India's Ranbaxy Laboratories is reporting favorable results from a malaria drug at the end of a Phase II clinical trial
You may also be interested in...
Ranbaxy's Anti-Malarial Approval Makes It First Indian Firm To Fully Develop An NCE
MUMBAI - For Ranbaxy Laboratories Ltd., it has been nearly a decade-long bumpy ride to discover and develop its anti-malarial compound, but India's regulator - the Drug Controller General of India - finally granted the company a conditional approval to market the compound
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.